

# Joseph R Osborne

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7291956/publications.pdf>

Version: 2024-02-01

90  
papers

3,565  
citations

172457

29  
h-index

138484

58  
g-index

95  
all docs

95  
docs citations

95  
times ranked

5557  
citing authors

#	ARTICLE	IF	CITATIONS
1	[ <sup>89</sup> Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 783-785.	6.4	4
2	<sup>68</sup> Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study. <i>Translational Oncology</i> , 2022, 15, 101242.	3.7	10
3	Pilot study of the diagnostic utility of <sup>89</sup> Zr- <sup>125</sup> I-AB2M and <sup>68</sup> Ga-PSMA-1 PET imaging and multiparametric MRI in localized prostate cancer. <i>Prostate</i> , 2022, , .	2.3	8
4	Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of <sup>225</sup> Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 77-77.	1.6	1
5	Quantitative assessment of PSMA imaging before and after <sup>177</sup> Lu-PSMA-617 treatment in a Ph I/II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 37-37.	1.6	0
6	Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- <sup>225</sup> Ac-J591 for chemo-naïve metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS216-TPS216.	1.6	2
7	Dynamic <sup>68</sup> Ga-DOTATATE PET/MRI in the Diagnosis and Management of Intracranial Meningiomas. <i>Radiology Imaging Cancer</i> , 2022, 4, e210067.	1.6	6
8	Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [ <sup>68</sup> Ga]-DOTATATE PET/MRI analysis in patients with meningioma. <i>Scientific Reports</i> , 2022, 12, .	3.3	10
9	Phase I/II study of <sup>225</sup> Ac-J591 plus <sup>177</sup> Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5100-TPS5100.	1.6	1
10	Self-reported race and zip code by men with prostate cancer in New York City and association with access to PSMA PET scans.. <i>Journal of Clinical Oncology</i> , 2022, 40, e17007-e17007.	1.6	0
11	[ <sup>68</sup> Ga]-DOTATATE PET/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab012.	0.7	20
12	Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted <sup>125</sup> I-emitting radionuclide therapies in metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2021, 81, 279-285.	2.3	14
13	A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2642-2651.	6.4	26
14	A phase I/II dose-escalation study of fractionated and multiple dose <sup>225</sup> Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS188-TPS188.	1.6	2
15	Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 630589.	2.8	26
16	Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.. <i>Journal of Clinical Oncology</i> , 2021, 39, 120-120.	1.6	1
17	Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 158-158.	1.6	1
18	Phase I study of <sup>225</sup> Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5015-5015.	1.6	24

#	ARTICLE	IF	CITATIONS
19	NEIM-05. [GA68]DOTATATE PET/MRI-BASED RADIOSURGICAL RESPONSE ASESSEMENT IN MENINGIOMA. Neuro-Oncology Advances, 2021, 3, iv7-iv7.	0.7	0
20	Prostate-Specific Membrane Antigen Positron Emission Tomography and the New Algorithm for Patients With Prostate Cancer Prior to Prostatectomy. JAMA Oncology, 2021, 7, 1642.	7.1	3
21	A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2021, 19, 447-456.	1.9	3
22	Review of commonly used prostate specific PET tracers used in prostate cancer imaging in current clinical practice. Clinical Imaging, 2021, 79, 278-288.	1.5	8
23	Utility of [18F]-Fluoroestradiol (FES) PET/CT with dedicated brain acquisition in differentiating brain metastases from post treatment change in estrogen receptor-positive breast cancer. Neuro-Oncology Advances, 2021, 3, v178.	0.7	2
24	Molecular Imaging of Striatal Dopaminergic Neuronal Loss and the Neurovascular Unit in Parkinson Disease. Frontiers in Neuroscience, 2020, 14, 528809.	2.8	13
25	Phase I trial of docetaxel plus lutetium-177-labeled anti- <sup>68</sup> prostate-specific membrane antigen monoclonal antibody J591 (177Lu- <sup>68</sup> J591) for metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 848.e9-848.e16.	1.6	29
26	Pilot Study of Hyperfractionated Dosing of Lutetium-177- <sup>68</sup> Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. Oncologist, 2020, 25, 477-e895.	3.7	26
27	Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 5560-5560.	1.6	9
28	Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 114-114.	1.6	17
29	Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 45-45.	1.6	1
30	Carotid Plaque Positron Emission Tomography Imaging and Cerebral Ischemic Disease. Stroke, 2019, 50, 2072-2079.	2.0	24
31	Association of Black Race With Prostate Cancer- <sup>68</sup> Specific and Other-Cause Mortality. JAMA Oncology, 2019, 5, 975.	7.1	288
32	Gallium- <sup>68</sup> DOTATATE PET in the Evaluation of Intracranial Meningiomas. Journal of Neuroimaging, 2019, 29, 650-656.	2.0	55
33	Phase 1/2 study of fractionated dose lutetium- <sup>177</sup> -labeled anti- <sup>68</sup> prostate-specific membrane antigen monoclonal antibody J591 ( <sup>177</sup> Lu- <sup>68</sup> J591) for metastatic castration-resistant prostate cancer. Cancer, 2019, 125, 2561-2569.	4.1	100
34	Presynaptic dopamine deficit in minimally conscious state patients following traumatic brain injury. Brain, 2019, 142, 1887-1893.	7.6	32
35	Cancer Health Impact Program (CHIP): Identifying Social and Demographic Associations of mHealth Access and Cancer Screening Behaviors Among Brooklyn, New York, Residents. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 478-485.	2.5	3
36	Thyroid Cancer Bone Metastasis. Clinical Nuclear Medicine, 2019, 44, e465-e471.	1.3	22

#	ARTICLE	IF	CITATIONS
37	Phase I/II dose-escalation trial of fractionated dose <sup>177</sup> Lu-J591 plus <sup>177</sup> Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, TPS339-TPS339.	1.6	1
38	Theragnostic Target, Prostate-Specific Membrane Antigen"Also Specific for Nonprostatic Malignancies. International Journal of Radiation Oncology Biology Physics, 2018, 101, 646-649.	0.8	6
39	Immediate Postablation <sup>18</sup> F-FDG Injection and Corresponding SUV Are Surrogate Biomarkers of Local Tumor Progression After Thermal Ablation of Colorectal Carcinoma Liver Metastases. Journal of Nuclear Medicine, 2018, 59, 1360-1365.	5.0	33
40	Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 217.	7.1	93
41	Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. International Journal of Radiation Oncology Biology Physics, 2017, 98, 726-732.	0.8	11
42	Repeatability of [ <sup>68</sup> Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. Molecular Imaging and Biology, 2017, 19, 944-951.	2.6	7
43	Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function <i>ERF</i> Mutations. Cancer Discovery, 2017, 7, 973-983.	9.4	94
44	Anatomic and functional imaging in the diagnosis of spine metastases and response assessment after spine radiosurgery. Neurosurgical Focus, 2017, 42, E5.	2.3	19
45	Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. European Urology, 2017, 71, 37-43.	1.9	64
46	PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?. International Journal of Environmental Research and Public Health, 2016, 13, 12.	2.6	24
47	Racial/Ethnic Disparities in Genomic Sequencing. JAMA Oncology, 2016, 2, 1070.	7.1	250
48	Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases. Spine Journal, 2016, 16, 291-298.	1.3	32
49	miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer. Translational Oncology, 2016, 9, 236-241.	3.7	16
50	Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after <sup>90</sup> Y radioembolization of colorectal liver metastases: A comparison with SUV <sub>max</sub> , SUV <sub>peak</sub> , and RECIST 1.0. European Journal of Radiology, 2016, 85, 1224-1231.	2.6	47
51	miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin. Experimental Cell Research, 2016, 348, 190-200.	2.6	67
52	FDG-Avid Intrathecal Inflammation Following Administration of Intrathecal Methotrexate. Clinical Nuclear Medicine, 2016, 41, 995-997.	1.3	2
53	Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. European Urology Focus, 2016, 2, 532-539.	3.1	23
54	ACR Practice Parameter for the Performance of Therapy With Unsealed Radiopharmaceutical Sources. Clinical Nuclear Medicine, 2016, 41, 106-117.	1.3	4

#	ARTICLE	IF	CITATIONS
55	A Perspective of the Future of Nuclear Medicine Training and Certification. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 88-96.	4.6	12
56	Guest Editorial. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 3-4.	4.6	1
57	Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. <i>EJNMMI Research</i> , 2016, 6, 7.	2.5	32
58	Stereotactic body radiotherapy for metastatic spinal sarcoma: a detailed patterns-of-failure study. <i>Journal of Neurosurgery: Spine</i> , 2016, 25, 52-58.	1.7	31
59	The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 523-531.	0.8	16
60	Striatal dopamine type 2 receptor availability in anorexia nervosa. <i>Psychiatry Research - Neuroimaging</i> , 2015, 233, 380-387.	1.8	34
61	Roundtable on the Future of Nuclear Medicine Training. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1966-1969.	5.0	2
62	Disparities in Castration-Resistant Prostate Cancer Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 1101-1103.	1.6	43
63	Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with <sup>131</sup> I-tositumomab. <i>Leukemia and Lymphoma</i> , 2015, 56, 342-346.	1.3	10
64	A Phase I/II Study for Analytic Validation of <sup>89</sup> Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5277-5285.	7.0	163
65	Comparison of <sup>18</sup> F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1674-1680.	5.0	92
66	Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes. <i>Clinical Colorectal Cancer</i> , 2015, 14, 296-305.	2.3	40
67	<sup>89</sup> Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2093-2105.	6.4	130
68	Utility of <sup>18</sup> F-FDG PET in clinical neuroendocrine prostate cancer. <i>Prostate</i> , 2014, 74, 1153-1159.	2.3	55
69	<sup>99m</sup> Tc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1791-1798.	5.0	125
70	Pairwise comparison of <sup>89</sup> Zr- and <sup>124</sup> I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 985-994.	6.4	65
71	A Prospective Pilot Study of <sup>89</sup> Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy. <i>Journal of Urology</i> , 2014, 191, 1439-1445.	0.4	73
72	Cholecystokinin-Assisted Hydrodissection of the Gallbladder Fossa during FDG PET/CT-guided Liver Ablation. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 1704-1706.	2.0	7

#	ARTICLE	IF	CITATIONS
73	PSMA-targeted dendrimers: a patent evaluation (WO2012078534). Expert Opinion on Therapeutic Patents, 2013, 23, 665-668.	5.0	3
74	Prostate Specific Membrane Antigen-Based Therapeutics. , 2013, , 459-466.		0
75	Prostate-specific membrane antigen-based imaging. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 144-154.	1.6	96
76	Phase II Study of Lutetium-177 <sup>66</sup> -Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2013, 19, 5182-5191.	7.0	370
77	Phase II trial of 177lutetium radiolabeled anti-PSMA antibody J591 (177Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers.. Journal of Clinical Oncology, 2013, 31, 121-121.	1.6	1
78	Prostate Specific Membrane Antigen-Based Diagnostics. , 2013, , 445-457.		0
79	Review of Salvage Therapy for Biochemically Recurrent Prostate Cancer: The Role of Imaging and Rationale for Systemic Salvage Targeted Anti-Prostate-Specific Membrane Antigen Radioimmunotherapy. Advances in Urology, 2012, 2012, 1-8.	1.3	36
80	952 ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)-BASED RADIOIMMUNOTHERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A DECADE OF EXPERIENCE WITH RADIOLABELED (RL)-J591. Journal of Urology, 2012, 187, .	0.4	1
81	Tc-99m labeled small-molecule inhibitors of prostate-specific membrane antigen (PSMA): New molecular imaging probes to detect metastatic prostate adenocarcinoma (PC).. Journal of Clinical Oncology, 2012, 30, 173-173.	1.6	3
82	Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy. Blood, 2012, 120, 1636-1636.	1.4	1
83	A Worrisome Interventricular Septum. Journal of the American College of Cardiology, 2011, 58, e43.	2.8	2
84	Automated Framework for Digital Radiation Dose Index Reporting From CT Dose Reports. American Journal of Roentgenology, 2011, 197, 1170-1174.	2.2	16
85	18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers. Cancer Research, 2011, 71, 5164-5174.	0.9	113
86	Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,. Blood, 2011, 118, 3712-3712.	1.4	1
87	Anti <sup>66</sup> prostate <sup>66</sup> -specific membrane antigen <sup>66</sup> -based radioimmunotherapy for prostate cancer. Cancer, 2010, 116, 1075-1083.	4.1	120
88	<sup>18</sup> F-FDG PET of Locally Invasive Breast Cancer and Association of Estrogen Receptor Status with Standardized Uptake Value: Microarray and Immunohistochemical Analysis. Journal of Nuclear Medicine, 2010, 51, 543-550.	5.0	86
89	Altered Biodistribution of Radiopharmaceuticals: Role of Radiochemical/Pharmaceutical Purity, Physiological, and Pharmacologic Factors. Seminars in Nuclear Medicine, 2010, 40, 220-241.	4.6	92
90	Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes. Cancer Research, 2005, 65, 9080-9088.	0.9	108